Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2012, Article ID 723096, 7 pages
http://dx.doi.org/10.1155/2012/723096
Research Article

Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy

1Wits Reproductive Health and HIV Institute, University of the Witwatersrand, 27516 Johannesburg, South Africa
2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, 21205 MD, USA

Received 19 January 2012; Revised 17 April 2012; Accepted 18 April 2012

Academic Editor: Susan Cu-Uvin

Copyright © 2012 Sheree Schwartz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Gray, M. J. Wawer, D. Serwadda et al., “Population-based study of fertility in women with HIV-1 infection in Uganda,” Lancet, vol. 351, no. 9096, pp. 98–103, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Homsy, R. Bunnell, D. Moore et al., “Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study,” PLoS ONE, vol. 4, no. 1, Article ID e4149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Myer, R. J. Carter, M. Katyal, P. Toro, W. M. El-Sadr, and E. J. Abrams, “Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study,” PLoS Medicine, vol. 7, no. 2, Article ID e1000229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. F. van Leth, P. Phanuphak, K. Ruxrungtham et al., “Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study,” Lancet, vol. 363, no. 9417, pp. 1253–1263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. SUSTIVA, Important Change in SUSTIVA (efavirenz) Package Insert- Change from Pregnancy Category C to D, SUSTIVA, Washington, DC, USA, 2005.
  6. SUSTIVA, Updated Label Information for Sustiva (efavirenz), SUSTIVA, Washington, DC, USA, 2010.
  7. N. Ford, L. Mofenson, K. Kranzer et al., “Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts,” AIDS, vol. 24, no. 10, pp. 1461–1470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. World Health Organization, A Systematic Review of the Teratogenicity of Efavirenz, World Health Organization, Geneva, Switzerland, 2009.
  9. N. Ford, A. Calmy, and L. Mofenson, “Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis,” AIDS, vol. 25, no. 18, pp. 2301–2304, 2011. View at Publisher · View at Google Scholar
  10. D. K. Ekouevi, P. A. Coffie, E. Ouattara et al., “Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS databases, abidjan, Côte d'Ivoire,” Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. 2, pp. 183–187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Bera, K. McCausland, R. Nonkwelo, B. Mgudlwa, S. Chacko, and B. Majeke, “Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional south african hospital,” AIDS, vol. 24, no. 2, pp. 283–289, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. World Health Organization, Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2010 rev, World Health Organization, Geneva, Switzerland, 2010.
  13. South African Department of Health, Clinical Guidelines for the Management of HIV & AIDS in Adults and Adolescents, South African Department of Health, Cape Town, South Africa, 2010.
  14. S. R. Schwartz, S. H. Mehta, T. E. Taha, H. V. Rees, F. Venter, and V. Black, “High Pregnancy Intentions and Missed Opportunities for Patient-Provider Communication About Fertility in a South African Cohort of HIV-Positive Women on Antiretroviral Therapy,” AIDS and Behavior, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Nanda, C. S. Morrison, C. Kwok et al., “Discontinuation of oral contraceptives and depot medroxyprogesterone acetate among women with and without HIV in Uganda, Zimbabwe and Thailand,” Contraception, vol. 83, no. 6, pp. 542–548, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. F. van Leth, S. Andrews, B. Grinsztejn et al., “The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART,” AIDS, vol. 19, no. 5, pp. 463–471, 2005. View at Google Scholar · View at Scopus
  17. E. De Lazzari, A. León, J. A. Arnaiz et al., “Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts,” HIV Medicine, vol. 9, no. 4, pp. 221–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Antela, A. Ocampo, R. Gómez et al., “Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to cd4 cell counts: results of the TOSCANA study,” HIV Clinical Trials, vol. 11, no. 1, pp. 11–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. E. N. Ouattara, X. Anglaret, A. Y. Wong et al., “Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age,” AIDS, vol. 26, no. 5, pp. 625–634, 2012. View at Google Scholar
  20. British HIV Association (BHIVA), Guidelines for the Management of HIV Infection in Pregnant Women 2012. Working Draft, British HIV Association, London, UK, 2012.
  21. E. J. Schouten, A. Jahn, D. Midiani et al., “Prevention of mother-to-child transmission of HIV and the health-related millennium development goals: time for a public health approach,” The Lancet, vol. 378, no. 9787, pp. 282–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. M. Kitahata, S. J. Gange, A. G. Abraham et al., “Effect of early versus deferred antiretroviral therapy for HIV on survival,” New England Journal of Medicine, vol. 360, no. 18, pp. 1815–1826, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Cohen, Y. Q. Chen, M. McCauley et al., “Prevention of HIV-1 infection with early antiretroviral therapy,” New England Journal of Medicine, vol. 365, no. 6, pp. 493–505, 2011. View at Publisher · View at Google Scholar